

09921880

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653sxs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27 Oct 21 EVENTLINE has been reloaded
NEWS 28 Oct 24 BEILSTEIN adds new search fields
NEWS 29 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002
NEWS 31 Nov 18 DKILIT has been renamed APOLLIT
NEWS 32 Nov 25 More calculated properties added to REGISTRY
NEWS 33 Dec 02 TIBKAT will be removed from STN
NEWS 34 Dec 04 CSA files on STN
NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36 Dec 17 TOXCENTER enhanced with additional content
NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN
NEWS 38 Dec 30 ISMEC no longer available
NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 40 Jan 21 NUTRACEUT offering one free connect hour in February 2003
NEWS 41 Jan 21 PHARMAML offering one free connect hour in February 2003
NEWS 42 Jan 29 Simultaneous left and right truncation added to COMPENDEX,

09921880

NEWS 43 Feb 13 ENERGY, INSPEC
NEWS 44 Feb 24 CANCERLIT is no longer being updated
NEWS 44 Feb 24 METADEX enhancements
NEWS 45 Feb 24 PCTGEN now available on STN
NEWS 46 Feb 24 TEMA now available on STN
NEWS 47 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 48 Feb 26 PCTFULL now contains images
NEWS 49 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:48:25 ON 04 MAR 2003

FILE 'REGISTRY' ENTERED AT 15:48:35 ON 04 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 MAR 2003 HIGHEST RN 496834-05-0
DICTIONARY FILE UPDATES: 3 MAR 2003 HIGHEST RN 496834-05-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

09921880

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s
nlakgkeesldsdlyaelrcmcikttsgihpkniqslevigkngthcnqveviat1kdgrkic1dpdaprikvqkklagdes/sqsp
L1 0 NLAKGKEESLDSDLYAELRCMCIKTTSGIHPKNIQSLEVIGKGTHCNQVEVIATLKDGKICLD
PDAPRIKKVQKKLAGDES/SQSP

=> s nlakgkeesldsdly/sqsp
L2 40 NLAKGKEESLDSDLY/SQSP

=> FIL BIOSIS MEDLINE CAPLUS EMBASE SCISEARCH PCTFULL USPATFULL USPAT2 EUROPATFULL
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
55.40 55.61

FILE 'BIOSIS' ENTERED AT 15:51:57 ON 04 MAR 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'MEDLINE' ENTERED AT 15:51:57 ON 04 MAR 2003

FILE 'CAPLUS' ENTERED AT 15:51:57 ON 04 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 15:51:57 ON 04 MAR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 15:51:57 ON 04 MAR 2003
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'PCTFULL' ENTERED AT 15:51:57 ON 04 MAR 2003
COPYRIGHT (C) 2003 Univentio

FILE 'USPATFULL' ENTERED AT 15:51:57 ON 04 MAR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:51:57 ON 04 MAR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 15:51:57 ON 04 MAR 2003
COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

=> s 12
'SQSP' IS NOT A VALID FIELD CODE
'SQSP' IS NOT A VALID FIELD CODE
'SQSP' IS NOT A VALID FIELD CODE
L3 48 L2

=> dup rem 13
PROCESSING COMPLETED FOR L3
L4 45 DUP REM L3 (3 DUPLICATES REMOVED)

=> s 14 and (· Antimicrobial or bactericidal or fungicidal or microbicidal or
antibacterial or anti-bacterial or antifungal or anti-fungal or bactericide or fungicide
or antibiotic)
6 FILES SEARCHED...

L5 5 L4 AND (7 ANTIMICROBIAL OR BACTERICIDAL OR FUNGICIDAL OR MICROB
ICIDAL OR ANTIBACTERIAL OR ANTI-BACTERIAL OR ANTIFUNGAL OR ANTI-
FUNGAL OR BACTERICIDE OR FUNGICIDE OR ANTIBIOTIC)

=> s 14 and (Antimicrobial or bactericidal or fungicidal or microbicidal or antibacterial or anti-bacterial or antifungal or anti-fungal or bactericide or fungicide or antibiotic)
 L6 5 L4 AND (ANTIMICROBIAL OR BACTERICIDAL OR FUNGICIDAL OR MICROBIC
 IDAL OR ANTIBACTERIAL OR ANTI-BACTERIAL OR ANTIFUNGAL OR ANTI-FU
 NGAL OR BACTERICIDE OR FUNGICIDE OR ANTIBIOTIC)

=> s 14 and (Antimicrobial or bactericidal or fungicidal or microbicidal or antibacterial or anti-bacterial or antifungal or anti-fungal or bactericide or fungicide or bacteria or fungus or fungal or antibiotic)

7 FILES SEARCHED...

L7 10 L4 AND (ANTIMICROBIAL OR BACTERICIDAL OR FUNGICIDAL OR MICROBIC
 IDAL OR ANTIBACTERIAL OR ANTI-BACTERIAL OR ANTIFUNGAL OR ANTI-FU
 NGAL OR BACTERICIDE OR FUNGICIDE OR BACTERIA OR FUNGUS OR FUNGAL
 OR ANTIBIOTIC)

=> s 17 and endocarditis

L8 1 L7 AND ENDOCARDITIS

=> d 17 1-10 pn py au ti so ab bib

L7 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS
 PATENT NO. KIND DATE

 PI WO 2002090568 A2 20021114
 PY 2002

IN Alsobrook, John P., II; Anderson, David W.; Boldog, Ferenc L.; Burgess, Catherine E.; Casman, Stacie J.; Edinger, Schlotmit R.; Ellerman, Karen; Gangolli, Esha A.; Gerlach, Valerie L.; Gorman, Linda; Gunther, Erik; Herrmann, John L.; Ji, Weizhen; Lepley, Denise M.; Lewin, David A.; Li, Li; Macdougall, John R.; Malyankar, Uriel M.; Mezes, Peter D.; Padigaru, Muralidhara; Paturajan, Meera; Peyman, John A.; Rastelli, Luca; Rieger, Daniel K.; Rothenberg, Mark E.; Shenoy, Suresh G.; Smithson, Glennda; Spytek, Kimberly A.; Stone, David J.; Taupier, Raymond J., Jr.; Tchernev, Velizar T.; Vernet, Corine A. M.; Voss, Edward Z.; Zerhusen, Bryan D.; Zhong, Haihong; Miller, Charles E.

TI Human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses

SO PCT Int. Appl., 491 pp.
 CODEN: PIXXD2

AB Disclosed herein are 62 cDNA sequences that encode novel human polypeptides that are members of the following protein families: trypsin, germline oligomeric matrix protein, neuromedin U25, caldecrin, neural cell adhesion protein, ADAMTS 12, CASPR4, ADAMS-TS3, gliacolin, aminopeptidase N, adiponectin, trypsin III, tissue kallikrein, .beta.-transforming growth factor, diphthamide synthesis protein, WECHE lungkine, ADAM-TS7, palmitoyl-protein thioesterase-2I, betacellulin, small inducible cytokine A23, granulocyte colony-stimulating factor, platelet basic protein 2, brain natriuretic peptide, serine protease, acyl-CoA-binding protein, elastase IV, collagen, viral receptor, and cathepsin L2. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivs., variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

AN 2002:869107 CAPLUS

DN 137:364443

TI Human cDNA sequences and their encoded proteins and diagnostic and

09921880

therapeutic uses

IN Alsobrook, John P., II; Anderson, David W.; Boldog, Ferenc L.; Burgess, Catherine E.; Casman, Stacie J.; Edinger, Schlomit R.; Ellerman, Karen; Gangolli, Esha A.; Gerlach, Valerie L.; Gorman, Linda; Gunther, Erik; Herrmann, John L.; Ji, Weizhen; Lepley, Denise M.; Lewin, David A.; Li, Li; Macdougall, John R.; Malyankar, Uriel M.; Mezes, Peter D.; Padigaru, Muralidhara; Patturajan, Meera; Peyman, John A.; Rastelli, Luca; Rieger, Daniel K.; Rothenberg, Mark E.; Shenoy, Suresh G.; Smithson, Glennda; Spytek, Kimberly A.; Stone, David J.; Taupier, Raymond J., Jr.; Tchernev, Velizar T.; Vernet, Corine A. M.; Voss, Edward Z.; Zerhusen, Bryan D.; Zhong, Haihong; Miller, Charles E.

PA USA

SO PCT Int. Appl., 491 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002090568	A2	20021114	WO 2002-US14341	20020502
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2001-288935P	P	20010503		
	US 2001-289087P	P	20010507		
	US 2001-289620P	P	20010508		
	US 2001-289621P	P	20010508		
	US 2001-289817P	P	20010509		
	US 2001-289818P	P	20010509		
	US 2001-290194P	P	20010511		
	US 2001-290753P	P	20010514		
	US 2001-291189P	P	20010515		
	US 2001-291243P	P	20010516		
	US 2001-292001P	P	20010518		
	US 2001-292374P	P	20010521		
	US 2001-292587P	P	20010522		
	US 2001-293107P	P	20010523		
	US 2001-293589P	P	20010524		
	US 2001-293747P	P	20010525		
	US 2001-294110P	P	20010529		
	US 2001-294434P	P	20010530		
	US 2001-312192P	P	20010814		
	US 2001-313173P	P	20010817		
	US 2001-313187P	P	20010817		
	US 2001-318728P	P	20010912		
	US 2001-318744P	P	20010912		
	US 2001-335910P	P	20011115		
	US 2001-333891P	P	20011128		
	US 2001-333942P	P	20011128		
	US 2002-345776P	P	20020103		
	US 2002-345220P	P	20020104		
	US 2002-136071	A	20020501		

09921880

L7 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS
PATENT NO. KIND DATE

PI WO 9934818 A1 19990715
AU 9922189 A1 19990726
PY 1999
1999
IN Damon, Inger K.; Moss, Bernard
TI Broad spectrum chemokine antagonist protein from molluscum contagiosum virus, and therapeutic use
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
AB The invention relates to a purified protein that antagonizes the ability of chemokines (CC and CXC) to attract leukocytes (monocytes, lymphocytes, and neutrophils), and it's use as an anti-inflammatory and antiviral agent. A method for treating a chemokine-related immunopathol. disorder in a subject by administering a therapeutically effective amt. of an anti-inflammatory protein, MCVCC, encoded by the molluscum contagiosum virus (MCV) gene MC148 (genome location from about base-pair 166,992 to base-pair 167,303 of MCV, or a biol. active fragment thereof) is provided. A method for treating a subject having or at risk of having an HIV infection or disorder by administering a therapeutically effective amt. of this anti-inflammatory protein is also provided. A pharmaceutical compn. contg. at least one dose of an anti-inflammatory protein having the amino acid sequence of a protein encoded by the MCV genome from about base-pair 166,992 to base-pair 167,303, or a biol. active fragment thereof, in a therapeutically acceptable carrier, is also provided.
AN 1999:451203 CAPLUS
DN 131:82961
TI Broad spectrum chemokine antagonist protein from molluscum contagiosum virus, and therapeutic use
IN Damon, Inger K.; Moss, Bernard
PA United States Dept. of Health and Human Services, USA
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 9934818 A1 19990715 WO 1999-US491 19990108
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9922189 A1 19990726 AU 1999-22189 19990108
PRAI US 1998-70945P P 19980109
WO 1999-US491 W 19990108
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS
PATENT NO. KIND DATE

PI WO 9915548 A2 19990401
WO 9915548 A3 19990617

09921880

AU 9897476 A1 19990412
EP 1015486 A2 20000705
JP 2001517422 T2 20011009

PY 1999
1999
1999
2000
2001

IN Krijgsveld, Jeroen; Zaat, Sebastianus Antonius Johannes; Dankert, Jacob; Kuijpers, Alma Johanna; Engbers, Gerardus Henricus Maria; Feijen, Jan

TI Recombinant **antimicrobial** peptides thrombocidin-1 (TC-1) and thrombocidin-2 (TC-2) isolated from human blood platelets

SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2

AB The present invention relates to isolated and recombinant **antimicrobial** peptides thrombocidin-1 (TC-1) and thrombocidin-2 (TC-2), or variants thereof, which comprise at least in part the sequence as shown in figure 1 indicated by the label TC-1 and TC-2, and have **antimicrobial** activity against gram-pos. and gram-neg. **bacteria**, for example Escherichia coli, Bacillus subtilis, Streptococcus sanguis, Streptococcus pneumoniae, Staphylococcus epidermidis, and Staphylococcus aureus, and/or against **fungi**, for example Candida albicans, C. glabrata, Cryptococcus neoformans, Aspergillus flavus, A. fumigatus, and Pseudoallescheria spec. The invention further relates to the use of said peptides, or variants thereof, for the prepn. of a medicament for the treatment of bacterial or **fungal** infections, such as endocarditis, in human and animals and the use of said peptides, or variants thereof, in release systems for prevention of bacterial or **fungal** infections in human and animals.

AN 1999:222951 CAPLUS
DN 130:271970

TI Recombinant **antimicrobial** peptides thrombocidin-1 (TC-1) and thrombocidin-2 (TC-2) isolated from human blood platelets

IN Krijgsveld, Jeroen; Zaat, Sebastianus Antonius Johannes; Dankert, Jacob; Kuijpers, Alma Johanna; Engbers, Gerardus Henricus Maria; Feijen, Jan

PA Academisch Ziekenhuis Bij De Universiteit Van Amsterdam, Neth.

SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9915548	A2	19990401	WO 1998-EP6183	19980925
	WO 9915548	A3	19990617		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9897476	A1	19990412	AU 1998-97476	19980925
	EP 1015486	A2	20000705	EP 1998-951480	19980925
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI			
	JP 2001517422	T2	20011009	JP 2000-512853	19980925
PRAI	EP 1997-202934	A	19970925		
	EP 1998-201411	A	19980501		
	WO 1998-EP6183	W	19980925		

09921880

L7 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS
PATENT NO. KIND DATE

PI WO 9013560 A1 19901115
US 5179196 A 19930112
AU 9055670 A1 19901129
EP 477200 A1 19920401
CA 2016018 AA 19901104

PY 1990
1993
1990
1992
1990

IN Johnson, Paul H.; Lazar, Jerome B.; Sze, Ping; Winant, Richard C.
TI Purification of proteins employing connective tissue activating peptide
III (CTAP-III) fusions
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2

AB A method for producing a heterologous protein with a microorganism
comprises producing a fusion protein contg. connective tissue activating
peptide III (CTAP-III), cleaving the fusion protein to produce CTAP-III
and a 2nd protein, and sepn. of the two proteins by ion exchange
chromatog. The CTAP-III and 2nd protein have different pIs, e.g. the pI
value of the 2nd protein is <6.5 or >8.5. CTAP-III-hirudin,
CTAP-III-laminin B1 peptide, and CTAP-III-platelet factor 4 fusion
proteins were produced with Escherichia coli, the fusion proteins were
cleaved with CNBr, and the peptides isolated and purified by e.g. anion
exchange chromatog.

AN 1991:490673 CAPLUS
DN 115:90673

TI Purification of proteins employing connective tissue activating peptide
III (CTAP-III) fusions
IN Johnson, Paul H.; Lazar, Jerome B.; Sze, Ping; Winant, Richard C.
PA SRI International, USA
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9013560	A1	19901115	WO 1990-US2432	19900501
	W: AU, FI, JP, KR, NO				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	US 5179196	A	19930112	US 1989-347371	19890504
	AU 9055670	A1	19901129	AU 1990-55670	19900501
	EP 477200	A1	19920401	EP 1990-907952	19900501
	R: DE, FR, GB, IT, NL				
	CA 2016018	AA	19901104	CA 1990-2016018	19900503
PRAI	US 1989-347371		19890504		
	WO 1990-US2432		19900501		
OS	MARPAT 115:90673				

L7 ANSWER 5 OF 10 USPATFULL
PI US 2002107186 A1 20020808
IN Prayaga, Sudhirdas K., O'Fallon, MO, UNITED STATES
Majumder, Kumud, Stamford, CT, UNITED STATES
Taillon, Bruce, Middletown, CT, UNITED STATES
Spaderna, Steven Kurt, Berlin, CT, UNITED STATES

Spytek, Kimberly, New Haven, CT, UNITED STATES
 MacDougall, John, New Haven, CT, UNITED STATES
 TI Novel polypeptides and nucleic acids encoding same
 AB The present invention provides novel isolated NOVX polynucleotides and polypeptides encoded by the NOVX polynucleotides. Also provided are the antibodies that immunospecifically bind to a NOVX polypeptide or any derivative, variant, mutant or fragment of the NOVX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the NOVX polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.
 AN 2002:199077 USPATFULL
 TI Novel polypeptides and nucleic acids encoding same
 IN Prayaga, Sudhirdas K., O'Fallon, MO, UNITED STATES
 Majumder, Kumud, Stamford, CT, UNITED STATES
 Taillon, Bruce, Middletown, CT, UNITED STATES
 Spaderna, Steven Kurt, Berlin, CT, UNITED STATES
 Spytek, Kimberly, New Haven, CT, UNITED STATES
 MacDougall, John, New Haven, CT, UNITED STATES
 PI US 2002107186 A1 20020808
 AI US 2001-755665 A1 20010104 (9)
 PRAI US 2000-174724P 20000106 (60)
 US 2000-175434P 20000111 (60)
 US 2000-175488P 20000111 (60)
 US 2000-175696P 20000112 (60)
 US 2000-175743P 20000112 (60)
 US 2000-175819P 20000113 (60)
 US 2000-223524P 20000807 (60)
 DT Utility
 FS APPLICATION
 LREP Ivor R. Elrifi, Ph.D., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA, 02111
 CLMN Number of Claims: 43
 ECL Exemplary Claim: 1
 DRWN 1 Drawing Page(s)
 LN.CNT 9231
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 10 USPATFULL
 PI US 5849534 19981215
 IN Grotendorst, Gary R., Miami, FL, United States
 Iida, Naoko, Miami Beach, FL, United States
 TI DNA encoding leukocyte derived growth factor-2 (LDGF-2)
 AB A protein, Leukocyte Derived Growth Factor 2 (hereinafter LDGF2) having PDGF-like activity is described. LDGF2 reacts with PDGF receptors and possesses mitogenic and/or chemotactic activity for various cell types, particularly connective tissue cells. LDGF2 may be used as the active ingredient in therapeutic compositions, e.g. wound healing compositions, or even further may be used as an additive to cell culture media for the purpose of stimulating cell growth. The protein has a molecular weight of about 7000 daltons determined by SDS gel electrophoresis and is about 61 amino acids in length.
 AN 1998:157146 USPATFULL
 TI DNA encoding leukocyte derived growth factor-2 (LDGF-2)
 IN Grotendorst, Gary R., Miami, FL, United States
 Iida, Naoko, Miami Beach, FL, United States
 PA University of South Florida, Tampa, FL, United States (U.S. corporation)
 PI US 5849534 19981215
 AI US 1995-465095 19950605 (8)
 RLI Division of Ser. No. US 1994-179656, filed on 7 Jan 1994 which is a

continuation-in-part of Ser. No. US 1993-1177, filed on 7 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1990-472377, filed on 1 Feb 1990, now abandoned

DT Utility
 FS Granted
 EXNAM Primary Examiner: Kemmerer, Elizabeth C.
 LREP Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Hanley, Elizabeth A.
 CLMN Number of Claims: 24
 ECL Exemplary Claim: 1
 DRWN 24 Drawing Figure(s); 18 Drawing Page(s)
 LN.CNT 1666
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 10 USPATFULL
 PI US 5804176 19980908
 IN Grotendorst, Gary Robert, Lutz, FL, United States
 TI Compositions comprising leukocyte-derived growth factors and methods of administering same to facilitate wound healing
 AB A gene encoding a leukocyte-derived growth factor (LDGF) has been isolated, cloned and sequenced. LDGF is believed to correspond to a PDGF-like monocyte-derived growth factor with chemotactic activity which is found in human wound fluid. Protease-resistant and other analogues of LDGF, as well as recombinant LDGF of native amino acid sequence, may now be produced by gene expression in transformed hosts.
 AN 1998:108016 USPATFULL
 TI Compositions comprising leukocyte-derived growth factors and methods of administering same to facilitate wound healing
 IN Grotendorst, Gary Robert, Lutz, FL, United States
 PA The University of South Florida, Tampa, FL, United States (U.S. corporation)
 PI US 5804176 19980908
 AI US 1995-416500 19950404 (8)
 RLI Continuation of Ser. No. US 1993-77312, filed on 14 Jun 1993, now abandoned which is a continuation of Ser. No. US 1990-472377, filed on 1 Feb 1990, now abandoned
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Kemmerer, Elizabeth C.
 LREP DeConti, Jr., Giulio A., Hanley, Elizabeth A. Lahive & Cockfield
 CLMN Number of Claims: 13
 ECL Exemplary Claim: 1
 DRWN 9 Drawing Figure(s); 9 Drawing Page(s)
 LN.CNT 1396
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 10 USPATFULL
 PI US 5179196 19930112
 IN Johnson, Paul H., Menlo Park, CA, United States
 Sze, Ping, Palo Alto, CA, United States
 Winant, Richard C., Palo Alto, CA, United States
 Lazar, Jerome B., Sunnyvale, CA, United States
 TI Purification of proteins employing CTAP-III fusions
 AB The present invention provides a process for the recovery of heterologous proteins from CTAP-III fusion proteins comprising expressing a fusion protein having a first amino acid sequence, a second amino acid sequence, and a selectable site which may be cleaved to provide first and second polypeptide fragments, respectively, wherein the first amino acid fragment is homologous to CTAP-III, and the first and second fragments have different pI values; cleaving the fusion protein to provide the first and second fragments; and separating the

09921880

first and second fragments by ion exchange chromatography.
AN 93:3676 USPATFULL
TI Purification of proteins employing CTAP-III fusions
IN Johnson, Paul H., Menlo Park, CA, United States
 Size, Ping, Palo Alto, CA, United States
 Winant, Richard C., Palo Alto, CA, United States
 Lazar, Jerome B., Sunnyvale, CA, United States
PA SRI International, Menlo Park, CA, United States (U.S. corporation)
PI US 5179196 19930112
AI US 1989-347371 19890504 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Patterson, Jr., Charles L.; Assistant Examiner:
 Furman, Keith C.
LREP Morrison & Foerster
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 1630
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 10 USPATFULL
PI US 5164304 19921117
IN Johnson, Paul H., Menlo Park, CA, United States
 Lazar, Jerome B., Sunnyvale, CA, United States
 Sohel, Indira, Fremont, CA, United States
 Waleh, Nahid S., Palo Alto, CA, United States
TI Method and vectors for stabilizing hirudin and human laminin B.sub.1
 expression
AB A method for obtaining heterologous peptides from fusion proteins
 wherein at least one of the fusion components is connective
 tissue-activating peptide-III is provided. Hirudin, a laminin B.sub.1
 peptide and platelet factor 4 are polypeptides expressed using this
 method. DNA sequences encoding the fusion protein, vectors containing
 these sequences and transformed prokaryotic hosts useful in practicing
 the method of the present invention are also provided.
AN 92:94994 USPATFULL
TI Method and vectors for stabilizing hirudin and human laminin B.sub.1
 expression
IN Johnson, Paul H., Menlo Park, CA, United States
 Lazar, Jerome B., Sunnyvale, CA, United States
 Sohel, Indira, Fremont, CA, United States
 Waleh, Nahid S., Palo Alto, CA, United States
PA SRI International, Menlo Park, CA, United States (U.S. corporation)
PI US 5164304 19921117
AI US 1989-347545 19890504 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Ellis, Joan
LREP Murphy, Lisabeth F., Benz, William H.
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 1708
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 10 USPATFULL
PI US 4897348 19900130
IN Johnson, Paul H., Menlo Park, CA, United States
 Waleh, Nahid S., Palo Alto, CA, United States

TI Recombinant materials and methods for producing human connective tissue-activating peptide-III and analogs thereof
AB A synthetic structural gene encoding CTAP-III or CTAP-III-Leu21 including adaptors for the carboxy and amino terminal ends of the gene which contain start and stop codons and convenient restriction sites for use in cloning the gene is described. The gene was designed for efficient expression in bacteria and to include two unique restriction sites for BamHI and XbaI. Plasmid expression vectors that are derivatives of pBR322 that contain a ColE1 insert which includes the expression control sequence and structural gene for colicin are also described. Constructs for expressing CTAP-III, CTAP-III-Leu21, CTAP-III or CTAP-III-Leu21 having a nonpolar pentapeptide fused to its amino terminus, and fusion proteins of such CTAP-III proteins and a colicin fragment are prepared by inserting the synthetic structural gene into the vectors at positions in phase with the colicin expression control sequence and under the control thereof.
AN 90:7626 USPATFULL
TI Recombinant materials and methods for producing human connective tissue-activating peptide-III and analogs thereof
IN Johnson, Paul H., Menlo Park, CA, United States
Waleh, Nahid S., Palo Alto, CA, United States
PA SRI International, Menlo Park, CA, United States (U.S. corporation)
PI US 4897348 19900130
AI US 1987-117916 19871104 (7)
RLI Continuation of Ser. No. US 1984-646259, filed on 30 Aug 1984, now abandoned which is a continuation-in-part of Ser. No. US 1983-526369, filed on 25 Aug 1983, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Tarcza, John E.
LREP Irell & Manella
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 1095
CAS INDEXING IS AVAILABLE FOR THIS PATENT.